Adynxx to present at EuroTIDES Conference on November 19th, 2014
SAN FRANCISCO, CALIF., October 29, 2014 – Scott Harris, Vice President, Regulatory Affairs & Product Development, will present at the 2014 EuroTIDES: Oligonucleotide and Peptide Research, Technology and Product Development conference on November 19th, 2014, at the Maritim proArte Hotel, Berlin, Germany. Mr. Harris’s presentation titled “Development Update of AYX1, a Novel Transcription Factor Decoy for the Prevention of Post-Surgical Pain” will provide a brief corporate overview and an update on development of the company’s lead product candidate, AYX1.
Adynxx, located in San Francisco, California, is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots – preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.
Adynxx’s lead compound, AYX1, is an investigational drug designed to prevent acute post-surgical pain and the transition to persistent or chronic pain with a single administration at the time of surgery. Funded by Domain Associates, Adynxx has successfully completed a safety Phase 1 and a proof-of-concept phase 2 clinical study of AYX1. Additional AYX drug candidate compounds designed to address a range of intractable neuropathic and inflammatory pain syndromes are also in active development.